TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06034054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nursing counceling
Description: * Providing an educational booklet containing information about pastry, verbally explaining the content of the prepared educational booklet.~* Answering the information and questions that the patient needs in addition, and receiving contact information in October.~* Monthly calls will be made to patients 6. providing information that the same tests will be performed again per month, if necessary, this monthly call counseling by reaching out without waiting indicating what they can receive.
Study: NCT04400721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block with ropivacaine 3.75mg/ml
Description: Single shot erector spinae block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block with ropivacaine 3.75mg/ml
Description: Single shot erector spinae block
Study: NCT01405638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: One-on-one client-centered counseling for lifestyle changes related to blood pressure control
Study: NCT04671251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEVI-007
Description: 50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.
Study: NCT03930602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Participants will receive fluvoxamine.
Study: NCT03638700

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisiGlide™ straight tip
Description: Arm C: Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisiGlide™ straight tip
Description: Arm C: Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisiGlide2™ straight tip
Description: Arm D: Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide1™ (tip according to the examiner)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisiGlide2™ straight tip
Description: Arm D: Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide1™ (tip according to the examiner)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisiGlide2™ straight tip
Description: Arm D: Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide1™ (tip according to the examiner)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisiGlide2™ straight tip
Description: Arm D: Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide1™ (tip according to the examiner)
Study: NCT03807947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial TAE - Bland embolization with 40-100 Microparticles
Description: TAE - Bland embolization with 40-100 Microparticles performed via left transradial access

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfemoral TAE - Bland embolization with 40-100 Microparticles
Description: TAE - Bland embolization with 40-100 Microparticles performed via right transfemoral access
Study: NCT00992693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (Virazole) Injection
Description: The drug is to be administered in a volume of 50-100 ml of normal saline to be infused over 30-40 minutes.~1) Loading dose: 33 mg/kg (maximum dose 2.64 g)(1 dose) 2) Followed by a dose of 16 mg/kg (max dose 1.28 g) every 6 hours for the first 4 days (15 doses) 3) Followed by a dose of 8 mg/kg (maximum dose 0.64 g) every 8 hours for the subsequent 6 days (18 doses) Ten day course of treatment with follow up between day 28 to day 60.
Study: NCT05025553

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Gut mobilization
Description: Polyethylene Glycol (PEG) at the Dose of 6.9 g/d Once a Day for 6 Month. Children were observed and tested at baseline (T0), 1 month (T1) and 6 months (T2) after gut mobilization.
Study: NCT04119778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise, Tai chi
Description: They are aerobic and mind-body exercise respectively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise, Tai chi
Description: They are aerobic and mind-body exercise respectively.
Study: NCT03194594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride, dexamethasone, and combination of two drugs
Description: After receiving by IRB approval and obtaining informed consent from patients, 93 patients who were aged between 18 and 70 years old and classified as American Society of Anesthesiologists (ASA) classes I and II. Afterward, the patients are randomly (sealed envelopes) allocated into one of three treatment; Group K (n = 31) receives a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, Group D (n = 31) receives dexamethasone 0.5 mg/kg i.v. and a maximum dose of 8 mg plus 2 ml saline, and Group KD (n = 31) receiveds ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v. at 5 minutes after the induction of anesthesia in a double-blinded method.
Study: NCT04472273

Intervention type: PROCEDURE
Intervention: high-flow nasal cannula / classic nasal cannula
Description: The oxygen given with nasal cannula cannot be humidified, causing drying in mucous membranes at high flow rates of more than 4L/min and problems in patient compliance.This situation prevents us to increase the oxygen FiO2 rate applied to the patient above 40%.According to the nasal cannula high-flow nasal cannula where heated and humidified oxygen can be delivered, oxygen therapy can be applied at a flow rate of 25L/min.It provides high flows easily, prevents the airway epithelium from drying out and improves mucus cleansing, causing a decrease in anatomical dead space.It provides discharge of expired air in the upper airways.It increases alveolar ventilation.It offers a stream adjusted to all children.Flow and titration can be adjusted according to the child's weight and effect.

Intervention type: PROCEDURE
Intervention: high-flow nasal cannula / classic nasal cannula
Description: The oxygen given with nasal cannula cannot be humidified, causing drying in mucous membranes at high flow rates of more than 4L/min and problems in patient compliance.This situation prevents us to increase the oxygen FiO2 rate applied to the patient above 40%.According to the nasal cannula high-flow nasal cannula where heated and humidified oxygen can be delivered, oxygen therapy can be applied at a flow rate of 25L/min.It provides high flows easily, prevents the airway epithelium from drying out and improves mucus cleansing, causing a decrease in anatomical dead space.It provides discharge of expired air in the upper airways.It increases alveolar ventilation.It offers a stream adjusted to all children.Flow and titration can be adjusted according to the child's weight and effect.
Study: NCT03830073

Intervention type: GENETIC
Intervention: Measurement of VDR genetic polymorphism
Description: VDR genetic polymorphism will be measured by RFLP and correlated with viral, autoimmune markers.

Intervention type: GENETIC
Intervention: Measurement of VDR genetic polymorphism
Description: VDR genetic polymorphism will be measured by RFLP and correlated with viral, autoimmune markers.
Study: NCT03611452

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Episiotomy
Description: repair of perineal muscles and skin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Episiotomy
Description: repair of perineal muscles and skin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Episiotomy
Description: repair of perineal muscles and skin
Study: NCT03652129

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Disinfection
Description: Disinfection maneuver using LASER and nano irrigant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Disinfection
Description: Disinfection maneuver using LASER and nano irrigant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Disinfection
Description: Disinfection maneuver using LASER and nano irrigant
Study: NCT03724305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Therapy for Insomnia
Description: Mindfulness-based therapy for insomnia (MBTI) will use mindfulness-based stress reduction techniques to specifically target cognitive-emotional arousal associated with non-refractory insomnia.
Study: NCT02398266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast ultrasound of leg muscle with Sonazoid (Contrast ultrasound microvascular perfusion imaging)
Description: Skeletal muscle perfusion assessment of the thigh and calf skeletal muscle will be performed with contrast ultrasound of leg muscle with Sonazoid while at rest and during exercise stress

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast ultrasound of leg muscle with Sonazoid (Contrast ultrasound microvascular perfusion imaging)
Description: Skeletal muscle perfusion assessment of the thigh and calf skeletal muscle will be performed with contrast ultrasound of leg muscle with Sonazoid while at rest and during exercise stress
Study: NCT02613247

Intervention type: DEVICE
Group type: OTHER
Intervention: Hylan G-F 20
Description: Intra-articular injection of 6 mL Hylan G-F 20
Study: NCT02708524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senofilcon C Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Samfilcon A Contact Lens
Study: NCT01876901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)
Description: 2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) Whatever the mode of continuity restoration used, resection is the same in the two groups. It consists of total excision of the rectum and its mesorectum, that intervention should be performed by laparotomy or laparoscopy.~After surgical resection, the colon is exteriorized through the anus and attached to the buttock.~By day 6, exteriorized colon is resected and coloanal anastomosis is performed without preventive stoma derivation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colo-anal anastomosis (CAA)
Description: After the surgical resection, coloanal anastomosis is performed usually after completion of a reservoir J when it is possible. Preventive ostomy is performed most often.~In the absence of fistula, the patient will reoperation for stoma closure of its branch
Study: NCT03082079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESD
Description: Patient in ESD group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate
Study: NCT01719263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterVapor® treatment plus Optimal Medical Therapy
Description: Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
Study: NCT01846442

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA (0.25%)
Description: Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA (0.5%)
Description: Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA (1.0%)
Description: Vaginal suppository containing 1.0% (13 mg) DHEA; daily dosing with one suppository for 12 weeks.
Study: NCT00061269

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Videoscopic-Assisted Retroperitoneal Debridement (VARD)
Study: NCT02681991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renamezin capsule
Study: NCT01405638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: One-on-one client-centered counseling for lifestyle changes related to blood pressure control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: One-on-one navigation to guide participants through the process of being screened for colorectal cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: One-on-one navigation to guide participants through the process of being screened for colorectal cancer.
Study: NCT01870128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Steroid
Description: Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 15 to 25 mg PO per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination
Description: Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
Study: NCT02930850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rad-67 Pulse oximeter
Description: Noninvasive pulse oximeter that measures hemoglobin
Study: NCT02365636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-45070
Description: TV-45070 is an ointment applied topically twice daily to area of pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-45070
Description: TV-45070 is an ointment applied topically twice daily to area of pain.
Study: NCT00267774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angio-guided PCI
Study: NCT02365636

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The matching placebo ointment contained only the excipients of the active treatment; also applied topically twice daily to area of pain.
Study: NCT00355238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brivanib (active)
Description: Tablet, Oral, Brivanib 800 mg, once daily, until progression
Study: NCT03706235

Intervention type: OTHER
Intervention: Blood draw (venipuncture)
Description: Draw 40 mls of blood from eligible subjects. Process and ship samples to sponsor.

Intervention type: OTHER
Intervention: Blood draw (venipuncture)
Description: Draw 40 mls of blood from eligible subjects. Process and ship samples to sponsor.
Study: NCT02577315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
Study: NCT02512107

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Juice Plus+
Description: Dried fruit and vegetable juice capsule.
Study: NCT00526058

Intervention type: DEVICE
Group type: OTHER
Intervention: Secura then Futura
Description: Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.

Intervention type: DEVICE
Group type: OTHER
Intervention: Futura then Secura
Description: Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.
Study: NCT02512107

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT05866289

Intervention type: OTHER
Intervention: Prone position
Description: Each prone position session had a minimum duration of one hour and a maximum duration of 12 hours for a minimum of 3 hours per day.
Study: NCT03363009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimized group
Description: The data provided by the connected devices is analyzed daily; the patient receives a phone call in case of no realization of the objectives.

Intervention type: DEVICE
Group type: OTHER
Intervention: Control group
Description: Data will be recorded but not analyzed daily during the period of participation. The patient receives a phone call one time a week to answer possible questions and modify the prescription of physical activity if need.
Study: NCT03063983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Continuous oral cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Continuous oral methotrexate
Study: NCT02226029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipid emulsion
Description: 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~* Lipid emulsion 1: acid stable, particle size 0.6 µm~* Lipid emulsion 2: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm~* 13C-markers will be mixed with emulsions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipid emulsion
Description: 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~* Lipid emulsion 1: acid stable, particle size 0.6 µm~* Lipid emulsion 2: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm~* 13C-markers will be mixed with emulsions
Study: NCT04572425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guided imagery
Description: 10 minutes of guided imagery experience delivered on tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: 10 minutes of virtual reality experience delivered by Facebook Oculus Go VR device
Study: NCT01746784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N6022
Description: Intravenous solution of N6022 in normal saline administered by infusion pump over 1-8 minutes depending on the dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intravenous solution of 0.9% (weight/volume) NaCl administered by infusion pump over 1-8 minutes depending on dose of active drug used in same cohort
Study: NCT02131792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slanted recession of the lateral rectus muscle
Description: All patients who had intermittent exotropia with convergence weakness was enrolled to the slanted lateral rectus muscle recession group.
Study: NCT01072734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: Influenza vaccine
Study: NCT03932695

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose milk peptide
Description: what is the effect of milk peptides 1400mg on postprandial glycemia after a meal rich in carbohydrates (75g)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Dose milk peptide
Description: what is the effect of milk peptides 2800mg on postprandial glycemia after a meal rich in carbohydrates (75g)
Study: NCT02293278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. The workshops focus on the importance of PA and movement skills for preschool-aged children, understanding structured and unstructured play, practical activities related to movement skills, how to overcome barriers in facilitating PA, and using everyday materials to facilitate PA and active play. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention. The intervention is based on NASPE (2002) guidelines of not having children sedentary more than 60 mins at a time, having children accumulate 60 mins in structured and unstructured PA (active play) each day at MVPA, as well as 180 mins of total PA as recommended by the Canadian PA Guidelines for preschoolers.
Study: NCT01549171

Intervention type: DRUG
Intervention: Iloprost
Description: supplement in culture medium during culture in the lab. The concentration is 1 uM.

Intervention type: OTHER
Intervention: normal saline
Description: Supplement with vehicle only no Iloprost.